CD70 explained

CD70 molecule
Hgncid:11937
Symbol:CD70
Altsymbols:CD27LG, TNFSF7
Entrezgene:970
Omim:602840
Refseq:NM_001252
Uniprot:P32970
Chromosome:19
Arm:p
Band:13

CD70 (Cluster of Differentiation 70) is a protein that in humans is encoded by CD70 gene. CD70 is also known as a ligand for CD27.[1]

Expression

In physiological condition the expression of CD70 on immune cells is transient and tightly controlled. It is primarily expressed on highly activated T cells and B cells, as well as on NK cells and mature dendritic cells. CD70 expression on T and B cells is stimulated through triggering of T and B cell receptors and can be upregulated by cytokines such as IL-1α, IL-2, IL-12, GM-CSF and TNF-α, while IL-4 and IL-10 can decrease CD70 expression.[2] Expression of CD70 on mDCs and pDCs is induced with Toll-like receptor (TLR) triggering and CD40 ligation.[3] Also, CD70 can be induced on NK cells upon stimulation with IL-15.[4]

Functions

CD70 acts as a costimulatory molecule and plays an important role in the regulation of the immune system activation, specifically by improving T-cell and B-cell activation, proliferation and survival, leading to a more efficient immune response.[5]

CD70 on activated antigen presenting cells (APC) including dendritic cells and B cells binds to CD27 on T lymphocytes and provides costimulatory signals. The interaction between CD27 and CD70 leads to the recruitment of intracellular adaptor proteins, such as TRAF2 and TRAF5, which then activate signaling pathways, including the NF-κB and JNK pathway.[6] CD27 signaling stimulates naïve CD4+ T lymphocytes to differentiate into Th1 cells by activation the transcription factor T-bet.

In addition to its role in T-cell activation and proliferation, CD70 also plays a role in the regulation of B-cell activation and differentiation. Receptor engagement can also cause reverse signaling through CD70. CD70 reverse signaling activates the phosphatidylinositol-3 kinase (PI3K) and MAP kinase signaling pathways, leading to the activation of various transcription factors and the expression of genes involved in cell growth and survival.[7]

Clinical significance

Cancer

Some studies have shown that CD70 is overexpressed in several types of cancer, including Hodgkin's lymphoma and non-Hodgkin's lymphoma. CD70 is also found to be overexpressed in some types of solid tumors.[8] [9] [10] This overexpression of CD70 in cancer cells has been shown to promote cell proliferation and survival, and to inhibit apoptosis, leading to the development and progression of the cancer. It is therefore suggested that anti-CD70 antibodies might be a possible treatment for CD70 positive lymphomas as normal lymphocytes have low CD70 expression.[11]

Drug development

Recent research has focused on the potential therapeutic use of CD70 in cancer treatment. One strategy being investigated is the use of antibodies that target CD70. ARGX-110 is a CD70-specific antibody that is currently under investigation for the treatment of hematological malignancies. It is being developed by the Belgian company arGEN-X. In December 2013 a first part of a phase 1b trial was completed. In January 2014 a safety and efficacy phase of the study started.[12]

Vorsetuzumab mafodotin is a CD70-targeted antibody-drug conjugate that started clinical trials for renal cell carcinoma.[13]

See also

Notes and References

  1. Web site: NCBI.
  2. Nolte . Martijn A. . van Olffen . Ronald W. . van Gisbergen . Klaas P. J. M. . van Lier . René A. W. . May 2009 . Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology . Immunological Reviews . en . 229 . 1 . 216–231 . 10.1111/j.1600-065X.2009.00774.x. 19426224 . 32860864 .
  3. The CD70–CD27 interaction during the stimulation with dendritic cells promotes naive CD4+ T cells to develop into T cells producing a broad array of immunostimulatory cytokines in humans . 2023-02-08 . International Immunology . 10.1093/intimm/dxp056 . 2009 . Hashimoto-Okada . Mutsumi . Kitawaki . Toshio . Kadowaki . Norimitsu . Iwata . Satoshi . Morimoto . Chikao . Hori . Toshiyuki . Uchiyama . Takashi . 21 . 8 . 891–904 . 19556308 . 2433/86187 . free .
  4. Vossen . Mireille T. M. . Matmati . Mourad . Hertoghs . Kirsten M. L. . Baars . Paul A. . Gent . Mi-Ran . Leclercq . Georges . Hamann . Jörg . Kuijpers . Taco W. . van Lier . René A. W. . 2008-03-15 . CD27 Defines Phenotypically and Functionally Different Human NK Cell Subsets . The Journal of Immunology . en . 180 . 6 . 3739–3745 . 10.4049/jimmunol.180.6.3739 . 18322179 . 26953338 . 0022-1767. free .
  5. Borst . Jannie . Hendriks . Jenny . Xiao . Yanling . 2005-06-01 . CD27 and CD70 in T cell and B cell activation . Current Opinion in Immunology . Lymphocyte activation / Lymphocyte effector functions . en . 17 . 3 . 275–281 . 10.1016/j.coi.2005.04.004 . 15886117 . 0952-7915.
  6. Han . Bobby Kwanghoon . Olsen . Nancy J. . Bottaro . Andrea . 2016-02-01 . The CD27–CD70 pathway and pathogenesis of autoimmune disease . Seminars in Arthritis and Rheumatism . en . 45 . 4 . 496–501 . 10.1016/j.semarthrit.2015.08.001 . 26359318 . 0049-0172.
  7. Arens . Ramon . Nolte . Martijn A. . Tesselaar . Kiki . Heemskerk . Bianca . Reedquist . Kris A. . van Lier . René A. W. . van Oers . Marinus H. J. . 2004-09-15 . Signaling through CD70 Regulates B Cell Activation and IgG Production . The Journal of Immunology . 173 . 6 . 3901–3908 . 10.4049/jimmunol.173.6.3901 . 15356138 . 31566653 . 0022-1767. free .
  8. Junker . Kerstin . Hindermann . Winfried . von . Eggeling Ferdinand . Diegmann . Julia . Haessler . Kirstin . Schubert . Joerg . 2005-06-01 . Cd70: a new tumor specific biomarker for renal cell carcinoma . Journal of Urology . 173 . 6 . 2150–2153 . 10.1097/01.ju.0000158121.49085.ba. 15879877 .
  9. Held-Feindt . Janka . Mentlein . Rolf . 2002-03-07 . CD70/CD27 ligand, a member of the TNF family, is expressed in human brain tumors . International Journal of Cancer . 98 . 3 . 352–356 . 10.1002/ijc.10207 . 11920585 . 12298972 . 0020-7136. free .
  10. Hishima . Tsunekazu . Fukayama . Masashi . Hayashi . Yukiko . Fujii . Takeshi . Ooba . Takayo . Funata . Nobuaki . Koike . Morio . May 2000 . CD70 Expression in Thymic Carcinoma . The American Journal of Surgical Pathology . 24 . 5 . 742–746 . 10.1097/00000478-200005000-00014 . 10800994 . 0147-5185.
  11. Israel BF, Gulley M, Elmore S, Ferrini S, Feng WH, Kenney SC . Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas . Mol. Cancer Ther. . 4 . 12 . 2037–44 . 2005 . 16373719 . 10.1158/1535-7163.MCT-05-0253 . 1821535 .
  12. Web site: ARGX-110: first-in-class CD70-targeting antibody with unique mode of therapeutic action. arGEN-X. 28 February 2015. https://web.archive.org/web/20150309072113/http://www.argen-x.com/onco002/. 9 March 2015. dead.
  13. http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle_Print&ID=1872671&highlight=, Seattle Genetics Third Quarter 2013 Financial Report

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "CD70".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.